Next Article in Journal
Previous Article in Journal
Ethyl 7-Methyl-1-(4-nitrophenyl)-5-phenyl-3-(thiophen-2-yl)-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate
Article Menu

Export Article

Molbank 2017, 2017(2), M943; doi:10.3390/M943

Short Note
Department of Studies in Chemistry, Mangalore University, Mangalagangothri 574199, Karnataka, India
Department of Industrial Chemistry, Mangalore University, Mangalagangothri 574199, Karnataka, India
Author to whom correspondence should be addressed.
Academic Editor: Norbert Haider
Received: 15 May 2017 / Accepted: 6 June 2017 / Published: 10 June 2017


In the present investigation, the synthesis and spectroscopic characterization of N-(4-nitrophenyl)-2-{2-[3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetamide (2) is performed. The title compound (2) is synthesized by the reaction of 3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5- dihydro-1H-pyrazole-1-carbothioamide (1) with N-(4-nitrophenyl)maleimide. The cyclization of title compound is evidenced by FT-IR, NMR, and LCMS data.
thiazolidinone; pyrazoline; synthesis; maleimide

1. Introduction

The design, synthesis, and production of new heterocyclic molecules as therapeutic agents are the main objectives of organic and medicinal chemistry. A large number of drugs and biologically relevant molecules are heterocyclic in nature. Among the heterocyclic systems, there are numerous bioactive molecules comprised of five membered rings with two hetero atoms (i.e., nitrogen and sulfur). The thiazolidinone ring system is a core structure in various pharmaceutically important scaffolds and associated with various biological activities. Some prominent biological properties attributed to the thiazolidinone skeleton are antimicrobial [1], anticonvulsant [2], anti-HIV [3,4], anti-inflammatory [5], anticancer [6], antitubercular [7,8], antioxidant [9], antihistaminic [10], antiviral [11], and antidiabetic [12] activities. Motivated by the aforementioned findings and pursuing our studies on different heterocyclic compounds, we designed and synthesized a new substituted thiazolidinone derivative to test its potential biological utilities. The main objective of the present synthesis is to combine 4-thiazolidinone with substituted pyrazoline derivative.

2. Results

The synthetic pathway for title compound was carried out as outlined in Scheme 1. The substituted thiazolidinone derivative was obtained by the reaction of 3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole-1-carbothioamide with N-(4-nitrophenyl)maleimide under a reflux condition in glacial acetic acid [13,14]. The analytical and spectral data confirmed the structure and purity of the newly synthesized title compound (2).

3. Discussion

The formation of the thiazolidinone scaffold from pyrazoline thiocarboamide was confirmed by the IR spectral data. The NH stretching frequency was observed at 3269 cm−1. The stretching frequencies due to aromatic and aliphatic hydrogen appeared at 3088 cm−1 and 2962 cm−1, respectively. The stretching frequencies at 1678 cm−1 and 1660 cm−1 corresponded to thiazolidinone and amide C=O, respectively. The characteristic absorption band appeared at 1597 cm−1 corresponding to the C=N group. The absorption bands for NO2 asymmetric and symmetric stretching were seen at 1529 cm−1 and 1328 cm−1, respectively. The C–Cl stretching frequency gave an absorption band at 833 cm−1.
The 1H-NMR spectrum displayed characteristic systems of two sets of AMX patterns due to pyrazoline moiety and 5-(2-oxoethyl)-4-thiazolidinone fragments. The chemical shifts for two diastereotopic methylene protons HA and HM at position 4 and a methine proton HX at position 5 of the pyrazoline ring showed three doublet of doublets at δ 3.45 ppm (JAM = 17.6 Hz, JAX = 4.4 Hz), 4.05 ppm (JMA = 18.4 Hz, JMX = 11.2 Hz), and 5.77 ppm (JXA = 3.6 Hz, JXM = 11.2 Hz) and thiazolidinone oxoethyl moiety protons resonated at δ 2.73 ppm (JAM = 16.8 Hz, JAX = 4.0 Hz), 3.33 ppm (JMA = 16.4 Hz, JMX = 4.0 Hz), and 4.41 ppm (JXA = 3.6 Hz, JXM = 11.2 Hz), respectively. The singlet signal appeared at δ 10.75 ppm was assigned to the NH proton. The twelve aromatic protons appeared as a multiplet in the region 7.13–8.24 ppm. The methyl protons of isopropyl group appeared as a doublet at δ 1.16 ppm with J = 7.2 Hz, whereas the methine proton resonated as a multiplet in the region δ 2.84–2.89 ppm.
In the 13C-NMR spectrum, the signals at δ 187.8 ppm and 176.9 ppm corresponded to C-3 and C-7 carbonyl (C=O) carbons of thiazolidinone and amide group, respectively. The C-5 and C-12 carbons resonated signals at δ 169.6 and 159.7 ppm respectively which corresponded to C=N of thiazolidinone and pyrazoline moieties. The C-19 carbon displayed a signal at δ 148.0 ppm was due to ipso carbon attached to the p-nitrophenyl moiety. The C-2 carbon of the thiazolidinone ring displayed a signal at δ 49.9 ppm. The signals at δ 63.5 and 43.2 ppm attributed to the C-14 and C-13 carbons of the pyrazoline ring. The C-6 methylene carbon resonated a signal at δ 35.7 ppm. The signals for C-36 and C-37/C-38 carbons of isopropyl group resonated at δ 33.0 and 23.7 ppm, respectively. LCMS spectrum supported the purity and molecular weight of the compound and displayed a molecular ion peak m/z at 577.7 (M+ + 1), which corresponded to the molecular formula, C29H26ClN5O4S. As the title compound possesses two chiral centers, so the possibility of four optical isomers could be envisaged. However, no attempt has been made to separate the isomers.

4. Materials and Methods

All the reagents and solvents were purchased from Sigma-Aldrich India and used without further purification. The melting point was taken in an open capillary tube and was uncorrected. The purity of the compound was confirmed by thin layer chromatography using Merck (Darmstadt, Germany) silica gel 60 F254-coated aluminum plates. IR spectrum was recorded on Shimadzu-FTIR Infrared spectrometer (Shimadzu, Kyoto, Japan) (νmax in cm−1). 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra recorded on a Bruker Avance III (Bruker, Billerica, Massachusetts, MA, USA), 400 MHz in DMSO-d6 solvent with 5 mm PABBO BB-1H tubes and TMS as internal standard. LCMS was obtained using Agilent (Santa Clara, California, CA, USA) 1200 series LC and Micromass zQ spectrometer. Elemental analysis was carried out by using VARIO EL-III (Elementar Analysensysteme GmBH, Hanau, Germany).
The synthesis and crystal structure of the starting material, 3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole-1-carbothioamide (1) was described in our earlier work [15,16,17].
A mixture of 3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole-1-carbothioamide (10 mmol) and N-(4-nitrophenyl)maleimide (10 mmol) was refluxed for 5 h in glacial acetic acid (15 mL). Completion of the reaction was checked by thin layer chromatography and the reaction mixture was cooled to room temperature and poured onto ice cold water. The precipitate obtained was filtered off, washed with water, dried, and recrystallized in DMF. Yield was 74 %.
Melting point: 266–268 °C; LCMS: m/z = 577.7 (M+ + 1); FTIR: νmax (cm−1), 3269 (NH), 3088 (Ar-H), 2962 (Al-H), 1678 (thiazolidinone C=O), 1660 (amide C=O), 1597 (C=N), 1529 (C-NO2 asymmetric stretching), 1328 (C-NO2 symmetric stretching), 833 (C–Cl); 1H-NMR (400 MHz, DMSO-d6): δ ppm, 1.16 (d, 6H, CH3, J = 7.2 Hz), 2.84–2.89 (m, 1H, CH), 2.73 (dd, 1H, thiaz HA, JAM = 16.8 Hz, JAX = 4.0 Hz), 3.33 (dd, 1H, thiaz HM, JMA = 16.4 Hz, JMX = 4.0 Hz), 3.45 (dd, 1H, pyraz HA, JAM = 17.6 Hz, JAX = 4.4 Hz), 4.05 (dd, 1H, pyraz HM, JMA = 18.4 Hz, JMX = 11.2 Hz), 4.41 (dd, 1H, thiaz CH, JXA = 4.0 Hz, JXM = 11.2 Hz), 5.77 (dd, 1H, pyraz HX, JXA = 3.6 Hz, JXM = 11.2 Hz), 7.13–8.24 (m, 12H, Ar-H), 10.75 (s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6): δ ppm, 23.7 (C-37/C-38, CH3), 33.0 (C-36, CH), 35.7 (C-6, CH2), 43.2 (C-13, pyrazoline CH2), 49.9 (C-2, CH of thiazolidinone ring), 63.5 (C-14, pyrazoline CH), 118.8, 124.9, 125.5, 125.6, 126.8, 128.5, 129.0, 136.1, 136.2, 137.6, 137.7, 142.2, 144.8, 147.9, 148.0 (aromatic C′s), 159.7 (C-12, C=N of pyrazoline ring), 169.6 (C-5, C=N of thiazolidinone ring), 176.9 (C-7, amide C=O), 187.8 (C-3, thiazolidinone C=O); Elemental analysis: Calculated for C29H26ClN5O4S, C, 60.46 %; H, 4.55 %; N, 12.16 %. Found: C, 60.44 %; H, 4.58 %; N, 12.14 %.

5. Conclusions

In the present study, a simple and effective method of synthesizing a new heterocycle 5-substituted thiazolidinone integrated with a pyrazoline derivative was reported. The structure of the title compound was confirmed by analytical and spectroscopic data.

Supplementary Materials

The FTIR, 1H-NMR, 13C-NMR, and LCMS data are available online.
Supplementary File 1Supplementary File 2Supplementary File 3Supplementary File 4


The authors are thankful to the director, SAIF-STIC, Cochin University of Science and Technology for providing NMR data. VVS thanks Mangalore University for research facilities.

Author Contributions

V.V.S. performed the experiments; B.K.S. analyzed the data; B.N. guided throughout the research work.

Conflicts of Interest

The authors declare no conflict of interest.


  1. Patel, N.; Bux, F.B.; Parmar, V.; Singh, A. Synthesis and biological studies of novel thiazolidinones. Rasayan J. Chem. 2011, 4, 790–794. [Google Scholar]
  2. Gursoy, A.; Terzioglu, N. Synthesis and isolation of new regioisomeric 4-thiazolidinones and their anticonvulsant activity. Turk. J. Chem. 2005, 29, 247–254. [Google Scholar]
  3. Barreca, M.L.; Chimirri, A.; De Luca, L.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappala, M.; Balzarini, J.; De Clercq, E.; Pannecouque, C.; et al. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett. 2001, 11, 1793–1796. [Google Scholar] [CrossRef]
  4. Carbone, A. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Pharmaco 2002, 57, 747–751. [Google Scholar]
  5. Kumar, A.; Rajput, C.S.; Bhati, S.K. Synthesis of 3-[4′-(p-chlorophenyl)-thiazol-2'-yl]-2-[(substituted azetidinone/thiazolidinone)-aminomethyl]-6-bromoquinazolin-4-ones as anti-inflammatory agents. Bioorg. Med. Chem. 2007, 15, 3089–3096. [Google Scholar] [CrossRef] [PubMed]
  6. Li, W.; Wang, Z.; Gududuru, V.; Zbytek, B.; Slominski, A.T.; Dalton, J.T.; Miller, D.D. Structure activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res. 2007, 27, 883–888. [Google Scholar] [PubMed]
  7. Babaoglu, K.; Page, M.A.; Jones, V.C.; McNeil, M.R.; Dong, C.; Naismith, J.H.; Lee, R.E. Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg. Med. Chem. Lett. 2003, 13, 3227–3230. [Google Scholar] [CrossRef]
  8. Ilango, K.; Arunkumar, S. Synthesis and antitubercular activity of novel 2-aryl N-(3,4,5-trihydroxy benzamido)-4-thiazolidinone derivatives. Rasayan J. Chem. 2010, 3, 493–496. [Google Scholar]
  9. Geronikaki, A.A.; Pitta, E.P.; Liaras, K.S. Thiazoles and thiazolidinones as antioxidants. Curr. Med. Chem. 2013, 20, 4460–4480. [Google Scholar] [CrossRef] [PubMed]
  10. Vigorita, M.G.; Previtera, T.; Basile, M.; Fenech, G.; Pasquale, R.C.; Occhiuto, F.; Circosta, C. 3,3'-Di[1,3-thiazolidine-4-one]system. IV. Synthesis and pharmacological properties of 3,3(1,2-ethanediyl)bis [2-aryl-1,3-thiazolidine-4-one 1,1-dioxide] derivatives. Farmaco Sci. 1988, 43, 373–379. [Google Scholar] [PubMed]
  11. Ravichandran, V.; Jain, A.; Kumar, K.S.; Rajak, H.; Agarwal, R.K. Design, synthesis, and evaluation of thiazolidinone derivatives as antimicrobial and antiviral agents. Chem. Biol. Drug Des. 2011, 78, 464–470. [Google Scholar] [CrossRef] [PubMed]
  12. Murugan, R.; Anbazhagan, S.; Narayanan, S.S. Synthesis and in vivo antidiabetic activity of novel dispiropyrrolidines through [3+2] cycloaddition reactions with thiazolidinedione and rhodanine derivatives. Eur. J. Med. Chem. 2009, 44, 3272–3279. [Google Scholar] [CrossRef] [PubMed]
  13. Marrian, D.H. The condensation of N-substituted maleimides with thioureas. J. Chem. Soc. 1949, 384, 1797–1799. [Google Scholar] [CrossRef]
  14. Pankova, A.S.; Golubev, P.R.; Khlebnikov, A.F.; Yulvanov, A.; Kuznetsov, M.A. Thiazol-4-one derivatives from the reaction of monosubstituted thioureas with maleimides: Structures and factors determining the selectivity and tautomeric equilibrium in solution. Beilstein J. Org. Chem. 2016, 12, 2563–2569. [Google Scholar] [CrossRef] [PubMed]
  15. Narayana, B.; Salian, V.V.; Sarojini, B.K.; Jasinski, J.P. (2E)-1-(4-Chlorophenyl)-3-[4-(propan-2-yl)phenyl]prop-2-en-1-one. Acta Cryst. 2014, E70, o855. [Google Scholar] [CrossRef] [PubMed]
  16. Salian, V.V.; Narayana, B.; Sarojini, B.K.; Sindhupriya, E.S.; Madhu, L.N.; Rao, S. Biologically potent pyrazoline derivatives from versatile (2)-1-(4-chlorophenyl)-3-[4-(propan-2-yl)phenyl]prop-2-en-1-one. Lett. Drug Des. Discov. 2017, 14, 216–227. [Google Scholar] [CrossRef]
  17. Salian, V.V.; Narayana, B.; Sarojini, B.K.; Kumar, M.S.; Nagananda, G.S.; Byrappa, K.; Kudva, A.K. Spectroscopic, single crystal X-ray, Hirshfeld, in vitro and in silico biological evaluation of a new series of potent thiazole nucleus integrated with pyrazoline scaffolds. Spectrochim. Acta A Mol. Biomol. 2017, 174, 254–271. [Google Scholar] [CrossRef] [PubMed]
Scheme 1. Synthesis of N-(4-nitrophenyl)-2-{2-[3-(4-chlorophenyl)-5-[4-(propan-2-yl)-phenyl]-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetamide.
Scheme 1. Synthesis of N-(4-nitrophenyl)-2-{2-[3-(4-chlorophenyl)-5-[4-(propan-2-yl)-phenyl]-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetamide.
Molbank 2017 m943 sch001
Molbank EISSN 1422-8599 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top